Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints

This phase I–II study explored safety, immunomodulatory and clinical effects of lenalidomide (weeks 1–16) and alemtuzumab (weeks 5–16) in 23 patients with refractory chronic lymphocytic leukemia. Most patients had Rai stage III/IV disease and were heavily pretreated (median 4 prior therapies), and 6...

Descripción completa

Detalles Bibliográficos
Autores principales: Winqvist, Maria, Mozaffari, Fariba, Palma, Marzia, Eketorp Sylvan, Sandra, Hansson, Lotta, Mellstedt, Håkan, Österborg, Anders, Lundin, Jeanette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5222940/
https://www.ncbi.nlm.nih.gov/pubmed/27815572
http://dx.doi.org/10.1007/s00262-016-1922-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5222940/
https://www.ncbi.nlm.nih.gov/pubmed/27815572
http://dx.doi.org/10.1007/s00262-016-1922-6

Ejemplares similares